AQP4 and myeloid sarcoma: These AQP4-IgG autoantibodies drive complement-mediated inflammation and astrocyte necrosis within the CNS, in contrast to MS, where T-cell-mediated immune responses predominantly target myelin and oligodendrocytes (1, 4, 5).